Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adenocarcinoma | 19 | 2024 | 6401 | 1.790 |
Why?
|
Bile Duct Neoplasms | 8 | 2024 | 615 | 1.680 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 32 | 2025 | 11886 | 1.580 |
Why?
|
Carcinoma, Pancreatic Ductal | 12 | 2024 | 1756 | 1.570 |
Why?
|
Anus Neoplasms | 3 | 2024 | 336 | 1.480 |
Why?
|
Esophageal Neoplasms | 11 | 2024 | 1674 | 1.470 |
Why?
|
Pancreatic Neoplasms | 16 | 2024 | 5443 | 1.470 |
Why?
|
Cholangiocarcinoma | 8 | 2024 | 562 | 1.260 |
Why?
|
Esophagogastric Junction | 9 | 2024 | 351 | 1.220 |
Why?
|
Colorectal Neoplasms | 12 | 2025 | 6982 | 1.190 |
Why?
|
Stomach Neoplasms | 10 | 2024 | 1483 | 1.150 |
Why?
|
Antineoplastic Agents | 19 | 2024 | 13699 | 1.090 |
Why?
|
Neoplasms | 33 | 2024 | 22390 | 1.020 |
Why?
|
Protein Kinase Inhibitors | 13 | 2024 | 5707 | 1.010 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 3 | 2021 | 213 | 0.980 |
Why?
|
Angiopoietin-2 | 2 | 2025 | 185 | 0.910 |
Why?
|
Biliary Tract Neoplasms | 2 | 2023 | 187 | 0.900 |
Why?
|
Immunoconjugates | 2 | 2023 | 976 | 0.880 |
Why?
|
Ameloblastoma | 1 | 2021 | 42 | 0.720 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2023 | 957 | 0.720 |
Why?
|
Trifluridine | 3 | 2020 | 28 | 0.720 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2024 | 4064 | 0.720 |
Why?
|
Maximum Tolerated Dose | 9 | 2024 | 899 | 0.710 |
Why?
|
Jaw Neoplasms | 1 | 2021 | 72 | 0.710 |
Why?
|
Benzimidazoles | 3 | 2021 | 864 | 0.700 |
Why?
|
Antibodies, Monoclonal | 6 | 2023 | 9264 | 0.690 |
Why?
|
Receptor, erbB-3 | 3 | 2024 | 143 | 0.690 |
Why?
|
GTP Phosphohydrolases | 3 | 2024 | 524 | 0.650 |
Why?
|
Codon | 1 | 2021 | 599 | 0.640 |
Why?
|
Thymine | 3 | 2020 | 69 | 0.620 |
Why?
|
Camptothecin | 3 | 2016 | 600 | 0.620 |
Why?
|
Pyrrolidines | 3 | 2020 | 342 | 0.540 |
Why?
|
DNA Copy Number Variations | 2 | 2024 | 2055 | 0.520 |
Why?
|
Pyridines | 7 | 2021 | 2896 | 0.510 |
Why?
|
DNA Repair | 4 | 2021 | 2054 | 0.490 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1640 | 0.480 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2024 | 1616 | 0.470 |
Why?
|
Oligopeptides | 1 | 2020 | 1194 | 0.460 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.460 |
Why?
|
Deoxycytidine | 4 | 2024 | 888 | 0.450 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1629 | 0.430 |
Why?
|
Sulfonamides | 7 | 2024 | 1982 | 0.410 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 168 | 0.400 |
Why?
|
Mutation | 21 | 2024 | 30266 | 0.390 |
Why?
|
Aged | 53 | 2025 | 171790 | 0.390 |
Why?
|
Pyrazoles | 3 | 2021 | 2029 | 0.380 |
Why?
|
Paclitaxel | 5 | 2024 | 1735 | 0.360 |
Why?
|
Middle Aged | 56 | 2025 | 223740 | 0.360 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 5 | 2024 | 1769 | 0.350 |
Why?
|
Leucovorin | 2 | 2024 | 643 | 0.340 |
Why?
|
Neoadjuvant Therapy | 5 | 2024 | 2909 | 0.340 |
Why?
|
Tumor Microenvironment | 7 | 2024 | 3951 | 0.340 |
Why?
|
Humans | 105 | 2025 | 768887 | 0.340 |
Why?
|
Carcinoma, Medullary | 1 | 2010 | 116 | 0.340 |
Why?
|
Receptor, erbB-2 | 5 | 2024 | 2606 | 0.320 |
Why?
|
Isocitrate Dehydrogenase | 4 | 2024 | 958 | 0.310 |
Why?
|
Aged, 80 and over | 25 | 2024 | 59738 | 0.310 |
Why?
|
Adult | 43 | 2025 | 223818 | 0.300 |
Why?
|
Glycine | 3 | 2021 | 672 | 0.300 |
Why?
|
Molecular Targeted Therapy | 6 | 2021 | 2830 | 0.290 |
Why?
|
Ovarian Neoplasms | 1 | 2025 | 4919 | 0.290 |
Why?
|
Neutropenia | 3 | 2023 | 893 | 0.290 |
Why?
|
Treatment Outcome | 20 | 2025 | 65485 | 0.280 |
Why?
|
Pyrroles | 2 | 2010 | 1126 | 0.280 |
Why?
|
Fluorouracil | 2 | 2024 | 1655 | 0.280 |
Why?
|
Quinoxalines | 2 | 2021 | 297 | 0.280 |
Why?
|
Male | 58 | 2025 | 365249 | 0.270 |
Why?
|
Narration | 1 | 2009 | 223 | 0.270 |
Why?
|
Female | 61 | 2025 | 397464 | 0.260 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2024 | 330 | 0.260 |
Why?
|
Indoles | 2 | 2010 | 1836 | 0.250 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2023 | 10778 | 0.250 |
Why?
|
Membrane Proteins | 2 | 2021 | 7885 | 0.240 |
Why?
|
Clonorchiasis | 1 | 2024 | 5 | 0.230 |
Why?
|
Clonorchis sinensis | 1 | 2024 | 3 | 0.230 |
Why?
|
Pyrimidinones | 2 | 2024 | 386 | 0.230 |
Why?
|
Angiopoietin-1 | 1 | 2025 | 134 | 0.230 |
Why?
|
Aniline Compounds | 2 | 2024 | 1094 | 0.230 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2019 | 906 | 0.230 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 637 | 0.220 |
Why?
|
Pentoxifylline | 1 | 2023 | 53 | 0.220 |
Why?
|
Guanosine Triphosphate | 1 | 2024 | 315 | 0.220 |
Why?
|
Stomatitis, Aphthous | 1 | 2023 | 51 | 0.210 |
Why?
|
Neuregulin-1 | 1 | 2024 | 136 | 0.210 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2024 | 109 | 0.210 |
Why?
|
Behcet Syndrome | 1 | 2023 | 86 | 0.210 |
Why?
|
Mucin 5AC | 1 | 2023 | 96 | 0.210 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2024 | 5342 | 0.200 |
Why?
|
bcl-X Protein | 1 | 2024 | 412 | 0.200 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 90 | 0.200 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2024 | 259 | 0.200 |
Why?
|
Pyridones | 2 | 2024 | 819 | 0.190 |
Why?
|
Indazoles | 3 | 2019 | 306 | 0.190 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.190 |
Why?
|
Clobetasol | 1 | 2021 | 33 | 0.180 |
Why?
|
Interviews as Topic | 1 | 2009 | 2742 | 0.180 |
Why?
|
Gene Amplification | 2 | 2024 | 1099 | 0.180 |
Why?
|
Immune Evasion | 1 | 2024 | 376 | 0.180 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2020 | 428 | 0.180 |
Why?
|
Liver Failure, Acute | 1 | 2021 | 182 | 0.170 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2023 | 481 | 0.170 |
Why?
|
Phenylurea Compounds | 2 | 2021 | 531 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.160 |
Why?
|
Quinolines | 2 | 2023 | 772 | 0.160 |
Why?
|
Colonic Neoplasms | 2 | 2022 | 2543 | 0.160 |
Why?
|
Barrett Esophagus | 1 | 2023 | 495 | 0.160 |
Why?
|
Calciphylaxis | 1 | 2021 | 129 | 0.160 |
Why?
|
Drug Administration Schedule | 6 | 2019 | 4862 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1027 | 0.150 |
Why?
|
Bayes Theorem | 2 | 2024 | 2357 | 0.150 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4926 | 0.150 |
Why?
|
Uracil | 2 | 2020 | 210 | 0.150 |
Why?
|
Azetidines | 1 | 2019 | 152 | 0.150 |
Why?
|
Disease-Free Survival | 6 | 2021 | 6856 | 0.140 |
Why?
|
Pyridinium Compounds | 1 | 2017 | 81 | 0.140 |
Why?
|
Neoplasm Staging | 6 | 2021 | 11262 | 0.140 |
Why?
|
Organoplatinum Compounds | 1 | 2019 | 408 | 0.140 |
Why?
|
Double-Blind Method | 7 | 2021 | 12469 | 0.140 |
Why?
|
Enzyme Inhibitors | 2 | 2020 | 3724 | 0.140 |
Why?
|
Thyroid Neoplasms | 1 | 2010 | 2360 | 0.140 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 714 | 0.140 |
Why?
|
Area Under Curve | 3 | 2015 | 1645 | 0.130 |
Why?
|
Lipid Peroxidation | 1 | 2017 | 276 | 0.130 |
Why?
|
Genes, BRCA1 | 1 | 2020 | 756 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 1 | 2025 | 3744 | 0.130 |
Why?
|
Genomics | 4 | 2024 | 5928 | 0.130 |
Why?
|
Glutathione Peroxidase | 1 | 2017 | 259 | 0.130 |
Why?
|
Gene Fusion | 1 | 2019 | 357 | 0.130 |
Why?
|
Fatty Acids | 1 | 2024 | 1812 | 0.130 |
Why?
|
Nausea | 2 | 2016 | 682 | 0.130 |
Why?
|
Anorexia | 1 | 2016 | 152 | 0.130 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2014 | 5716 | 0.130 |
Why?
|
Cyclopentanes | 1 | 2015 | 87 | 0.120 |
Why?
|
Prognosis | 6 | 2024 | 30044 | 0.120 |
Why?
|
Cell Line, Tumor | 8 | 2024 | 17174 | 0.120 |
Why?
|
Neoplasms, Experimental | 1 | 2020 | 1231 | 0.120 |
Why?
|
Follow-Up Studies | 7 | 2024 | 39394 | 0.120 |
Why?
|
Antibodies | 1 | 2023 | 2422 | 0.120 |
Why?
|
Organic Chemicals | 1 | 2015 | 211 | 0.120 |
Why?
|
Tetrahydronaphthalenes | 1 | 2014 | 86 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5434 | 0.110 |
Why?
|
Analgesics | 1 | 2021 | 1072 | 0.110 |
Why?
|
DNA | 3 | 2024 | 7214 | 0.110 |
Why?
|
Cholecalciferol | 1 | 2019 | 557 | 0.110 |
Why?
|
Pyrimidines | 3 | 2015 | 3050 | 0.110 |
Why?
|
Anilides | 1 | 2017 | 414 | 0.110 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2017 | 664 | 0.110 |
Why?
|
Liver Neoplasms | 1 | 2009 | 4363 | 0.110 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2960 | 0.110 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2916 | 0.110 |
Why?
|
Piperazines | 1 | 2023 | 2553 | 0.110 |
Why?
|
Rectal Neoplasms | 1 | 2022 | 1183 | 0.100 |
Why?
|
Valine | 1 | 2014 | 410 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 1408 | 0.100 |
Why?
|
Drug Interactions | 1 | 2017 | 1421 | 0.100 |
Why?
|
Immunity, Innate | 1 | 2024 | 3080 | 0.100 |
Why?
|
Administration, Oral | 3 | 2016 | 4042 | 0.100 |
Why?
|
Cholecystitis | 1 | 2012 | 181 | 0.090 |
Why?
|
Carcinoma | 1 | 2023 | 2340 | 0.090 |
Why?
|
Animals | 15 | 2024 | 169408 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2024 | 3671 | 0.090 |
Why?
|
Albumins | 2 | 2024 | 577 | 0.090 |
Why?
|
Apoptosis | 3 | 2024 | 9528 | 0.090 |
Why?
|
Mice | 11 | 2024 | 82074 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1638 | 0.090 |
Why?
|
Gene Expression Profiling | 4 | 2024 | 9549 | 0.090 |
Why?
|
Piperidines | 1 | 2019 | 1669 | 0.090 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2014 | 614 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2016 | 641 | 0.090 |
Why?
|
DNA Damage | 1 | 2020 | 2472 | 0.090 |
Why?
|
Cisplatin | 1 | 2016 | 1661 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 426 | 0.090 |
Why?
|
Colitis, Ulcerative | 1 | 2022 | 1931 | 0.080 |
Why?
|
Crohn Disease | 1 | 2022 | 2297 | 0.080 |
Why?
|
Radiography, Abdominal | 1 | 2012 | 541 | 0.080 |
Why?
|
Health Promotion | 1 | 2021 | 2210 | 0.080 |
Why?
|
Pain | 2 | 2021 | 5100 | 0.080 |
Why?
|
Research Design | 1 | 2024 | 6213 | 0.080 |
Why?
|
Microfluidic Analytical Techniques | 2 | 2017 | 823 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4755 | 0.080 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2014 | 2063 | 0.070 |
Why?
|
Intestinal Diseases | 1 | 2012 | 505 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2059 | 0.070 |
Why?
|
Sepsis | 1 | 2021 | 2609 | 0.070 |
Why?
|
Survival Rate | 2 | 2019 | 12873 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2022 | 2445 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2014 | 1277 | 0.070 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2014 | 798 | 0.070 |
Why?
|
Cohort Studies | 2 | 2023 | 41800 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2017 | 3518 | 0.070 |
Why?
|
Sick Role | 1 | 2007 | 229 | 0.070 |
Why?
|
Melanoma | 2 | 2023 | 5709 | 0.070 |
Why?
|
Family Relations | 1 | 2009 | 318 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3238 | 0.070 |
Why?
|
Young Adult | 5 | 2021 | 60110 | 0.070 |
Why?
|
Phosphates | 1 | 2010 | 765 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1351 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2019 | 3442 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8664 | 0.060 |
Why?
|
Self-Help Groups | 1 | 2007 | 194 | 0.060 |
Why?
|
Internet | 2 | 2009 | 3112 | 0.060 |
Why?
|
Religion and Psychology | 1 | 2007 | 180 | 0.060 |
Why?
|
Pancreatitis | 1 | 2012 | 1087 | 0.060 |
Why?
|
Biomedical Research | 1 | 2021 | 3463 | 0.060 |
Why?
|
Transplantation, Homologous | 1 | 2014 | 4835 | 0.060 |
Why?
|
Edema | 2 | 2023 | 766 | 0.060 |
Why?
|
Chromosomes, Bacterial | 2 | 1982 | 281 | 0.060 |
Why?
|
Enterobacteriaceae | 2 | 1982 | 161 | 0.060 |
Why?
|
Tissue Distribution | 2 | 2019 | 2299 | 0.060 |
Why?
|
Intestinal Fistula | 2 | 2017 | 144 | 0.060 |
Why?
|
Religion | 1 | 2007 | 376 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3621 | 0.060 |
Why?
|
Enterobacter | 2 | 1982 | 44 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7460 | 0.050 |
Why?
|
Water | 1 | 2010 | 1421 | 0.050 |
Why?
|
Environmental Monitoring | 1 | 2010 | 1466 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6610 | 0.050 |
Why?
|
Xanthomonas campestris | 2 | 1993 | 7 | 0.050 |
Why?
|
Genes, myc | 1 | 2024 | 391 | 0.050 |
Why?
|
Intestinal Perforation | 2 | 2017 | 254 | 0.050 |
Why?
|
Glutarates | 1 | 2024 | 243 | 0.050 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13593 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2024 | 6546 | 0.050 |
Why?
|
Nucleotidyltransferases | 1 | 2024 | 242 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2024 | 268 | 0.050 |
Why?
|
Diarrhea | 2 | 2023 | 1319 | 0.050 |
Why?
|
Claudins | 1 | 2023 | 117 | 0.050 |
Why?
|
Prospective Studies | 2 | 2024 | 54950 | 0.050 |
Why?
|
DNA Transposable Elements | 2 | 2024 | 764 | 0.050 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2002 | 318 | 0.050 |
Why?
|
Oximes | 1 | 2023 | 303 | 0.050 |
Why?
|
GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 89 | 0.050 |
Why?
|
Tumor Escape | 1 | 2024 | 372 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2005 | 5150 | 0.050 |
Why?
|
Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 94 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2014 | 2250 | 0.050 |
Why?
|
Drug Combinations | 2 | 2020 | 2088 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2024 | 640 | 0.050 |
Why?
|
Ibuprofen | 1 | 2002 | 229 | 0.050 |
Why?
|
DNA Replication | 3 | 1983 | 1428 | 0.050 |
Why?
|
Conditioning, Operant | 1 | 2002 | 311 | 0.050 |
Why?
|
Klebsiella pneumoniae | 2 | 1982 | 253 | 0.050 |
Why?
|
Phthalazines | 1 | 2023 | 397 | 0.050 |
Why?
|
Breast Neoplasms | 3 | 2023 | 21187 | 0.050 |
Why?
|
Prolactin | 1 | 2003 | 627 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2024 | 81892 | 0.040 |
Why?
|
North America | 1 | 2024 | 1290 | 0.040 |
Why?
|
Cell Lineage | 2 | 2017 | 2576 | 0.040 |
Why?
|
Amyloid beta-Peptides | 2 | 2005 | 3912 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3538 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 631 | 0.040 |
Why?
|
Mice, Inbred BALB C | 3 | 2024 | 6232 | 0.040 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 304 | 0.040 |
Why?
|
United Nations | 1 | 2021 | 151 | 0.040 |
Why?
|
Lectins | 1 | 2002 | 490 | 0.040 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2002 | 458 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4651 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 417 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 2433 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2023 | 465 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 692 | 0.040 |
Why?
|
Thigh | 1 | 2021 | 239 | 0.040 |
Why?
|
B-Lymphocytes | 2 | 2003 | 4794 | 0.040 |
Why?
|
Organizational Objectives | 1 | 2021 | 426 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1737 | 0.040 |
Why?
|
Skin | 2 | 2023 | 4507 | 0.040 |
Why?
|
Adolescent | 3 | 2021 | 89247 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 592 | 0.040 |
Why?
|
Indolizines | 1 | 2017 | 30 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 620 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1748 | 0.040 |
Why?
|
Cyclic N-Oxides | 1 | 2017 | 72 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 854 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2015 | 5375 | 0.040 |
Why?
|
Lipid Peroxides | 1 | 2017 | 74 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 4053 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6673 | 0.040 |
Why?
|
Antioxidants | 1 | 2005 | 1673 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2205 | 0.040 |
Why?
|
Megakaryocytes | 1 | 2001 | 571 | 0.030 |
Why?
|
Hyperbilirubinemia | 1 | 2017 | 74 | 0.030 |
Why?
|
Esophagus | 1 | 2023 | 1043 | 0.030 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2017 | 146 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2024 | 22381 | 0.030 |
Why?
|
Proteomics | 2 | 2023 | 3913 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20244 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 2667 | 0.030 |
Why?
|
Activities of Daily Living | 2 | 2021 | 2433 | 0.030 |
Why?
|
Biological Evolution | 1 | 1982 | 1078 | 0.030 |
Why?
|
Cell Transdifferentiation | 1 | 2017 | 187 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1855 | 0.030 |
Why?
|
Epistaxis | 1 | 2017 | 117 | 0.030 |
Why?
|
Polysaccharides, Bacterial | 3 | 1995 | 582 | 0.030 |
Why?
|
Gram-Negative Aerobic Bacteria | 1 | 1995 | 8 | 0.030 |
Why?
|
Quality of Life | 3 | 2023 | 13510 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2002 | 1614 | 0.030 |
Why?
|
Survival Analysis | 2 | 2021 | 10115 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 331 | 0.030 |
Why?
|
Food-Drug Interactions | 1 | 2015 | 26 | 0.030 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2015 | 85 | 0.030 |
Why?
|
Japan | 1 | 2020 | 1418 | 0.030 |
Why?
|
Genes, Bacterial | 3 | 1991 | 1076 | 0.030 |
Why?
|
Carcinoma, Renal Cell | 1 | 2010 | 3200 | 0.030 |
Why?
|
Hippocampus | 2 | 2005 | 3786 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5803 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2017 | 457 | 0.030 |
Why?
|
Estradiol | 1 | 2002 | 1952 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2002 | 2892 | 0.030 |
Why?
|
Fentanyl | 1 | 1998 | 450 | 0.030 |
Why?
|
Urinary Retention | 1 | 1995 | 107 | 0.030 |
Why?
|
Behavior, Animal | 1 | 2002 | 1879 | 0.030 |
Why?
|
Urinary Catheterization | 1 | 1995 | 195 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2024 | 18366 | 0.030 |
Why?
|
Optic Atrophies, Hereditary | 1 | 1994 | 27 | 0.030 |
Why?
|
Communication | 1 | 2009 | 3908 | 0.030 |
Why?
|
Half-Life | 1 | 2015 | 651 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2016 | 478 | 0.030 |
Why?
|
Glucosephosphate Dehydrogenase | 1 | 1995 | 209 | 0.030 |
Why?
|
Mesoderm | 1 | 2017 | 679 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 550 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2010 | 8055 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2010 | 4300 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6512 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2014 | 20776 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3441 | 0.030 |
Why?
|
Cloning, Molecular | 4 | 2001 | 4168 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 567 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1866 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2277 | 0.030 |
Why?
|
Cadherins | 1 | 2017 | 906 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12563 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3554 | 0.030 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 2012 | 31 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9442 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 755 | 0.020 |
Why?
|
Transferases | 1 | 1991 | 71 | 0.020 |
Why?
|
Cell Death | 1 | 2017 | 1682 | 0.020 |
Why?
|
Bacterial Proteins | 3 | 1995 | 3839 | 0.020 |
Why?
|
Antigens, CD | 1 | 2002 | 4032 | 0.020 |
Why?
|
Triazoles | 1 | 1997 | 904 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2023 | 4528 | 0.020 |
Why?
|
Lymphocytes | 2 | 2014 | 2614 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1494 | 0.020 |
Why?
|
Stomatitis | 1 | 2013 | 271 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6320 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2350 | 0.020 |
Why?
|
Signal Transduction | 4 | 2019 | 23652 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3836 | 0.020 |
Why?
|
Gastroenteritis | 1 | 2012 | 236 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2041 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2024 | 7609 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2542 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1667 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4432 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6131 | 0.020 |
Why?
|
Acyltransferases | 1 | 1991 | 306 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 1998 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1887 | 0.020 |
Why?
|
Benzamides | 1 | 2015 | 1387 | 0.020 |
Why?
|
Pyrazines | 1 | 2015 | 1206 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1752 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1913 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2001 | 3408 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 600 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1073 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8559 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6805 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3709 | 0.020 |
Why?
|
DNA, Mitochondrial | 1 | 1994 | 871 | 0.020 |
Why?
|
Iron | 1 | 2017 | 1813 | 0.020 |
Why?
|
Multigene Family | 1 | 1991 | 1082 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2001 | 4940 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2017 | 11119 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2024 | 10486 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4123 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1894 | 0.020 |
Why?
|
Infection Control | 1 | 1995 | 984 | 0.020 |
Why?
|
Wisconsin | 1 | 2007 | 122 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 1993 | 1039 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2012 | 1195 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5905 | 0.020 |
Why?
|
Income | 1 | 2015 | 1878 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2017 | 3233 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2016 | 2009 | 0.020 |
Why?
|
Michigan | 1 | 2007 | 336 | 0.020 |
Why?
|
Sirolimus | 1 | 2013 | 1540 | 0.020 |
Why?
|
Fatty Liver | 1 | 2012 | 810 | 0.020 |
Why?
|
Water Pollutants, Chemical | 1 | 2010 | 359 | 0.020 |
Why?
|
Base Sequence | 5 | 1995 | 12430 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12093 | 0.020 |
Why?
|
Histones | 1 | 2016 | 2603 | 0.020 |
Why?
|
DNA, Bacterial | 3 | 1991 | 1478 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3311 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16735 | 0.010 |
Why?
|
Escherichia coli | 4 | 1991 | 4212 | 0.010 |
Why?
|
Time Perception | 1 | 2005 | 87 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2001 | 2749 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 3450 | 0.010 |
Why?
|
Attitude to Death | 1 | 2007 | 401 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2884 | 0.010 |
Why?
|
Phylogeny | 2 | 2001 | 2843 | 0.010 |
Why?
|
Anemia | 1 | 2013 | 1516 | 0.010 |
Why?
|
Algorithms | 1 | 2024 | 14199 | 0.010 |
Why?
|
Discrimination Learning | 1 | 2005 | 278 | 0.010 |
Why?
|
Colitis | 1 | 2012 | 1244 | 0.010 |
Why?
|
Glucose | 1 | 1995 | 4352 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4456 | 0.010 |
Why?
|
Molecular Sequence Data | 4 | 2001 | 17629 | 0.010 |
Why?
|
Culture | 1 | 2007 | 623 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12174 | 0.010 |
Why?
|
Time Factors | 3 | 2020 | 40266 | 0.010 |
Why?
|
Developing Countries | 1 | 2015 | 2906 | 0.010 |
Why?
|
Vibrio | 1 | 1983 | 40 | 0.010 |
Why?
|
Self Efficacy | 1 | 2007 | 643 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13677 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4784 | 0.010 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 1982 | 167 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7453 | 0.010 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2003 | 171 | 0.010 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2002 | 121 | 0.010 |
Why?
|
Injections | 1 | 2005 | 841 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2059 | 0.010 |
Why?
|
Microinjections | 1 | 2002 | 323 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 1998 | 3837 | 0.010 |
Why?
|
Hybridomas | 1 | 2003 | 444 | 0.010 |
Why?
|
Immunoglobulin Variable Region | 1 | 2003 | 420 | 0.010 |
Why?
|
RGS Proteins | 1 | 2001 | 76 | 0.010 |
Why?
|
Estrogen Receptor beta | 1 | 2002 | 171 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5334 | 0.010 |
Why?
|
Pheromones | 1 | 2001 | 93 | 0.010 |
Why?
|
Antibodies, Antinuclear | 1 | 2003 | 343 | 0.010 |
Why?
|
Mutagenesis, Insertional | 2 | 1995 | 662 | 0.010 |
Why?
|
Vitamin E | 1 | 2005 | 874 | 0.010 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2002 | 564 | 0.010 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1982 | 781 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 474 | 0.010 |
Why?
|
Salmonella typhimurium | 1 | 1982 | 348 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 478 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 1553 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2002 | 1890 | 0.010 |
Why?
|
Schizophrenia | 1 | 1997 | 6987 | 0.010 |
Why?
|
Estrogen Receptor alpha | 1 | 2002 | 581 | 0.010 |
Why?
|
Rats | 2 | 2005 | 23847 | 0.010 |
Why?
|
National Institute of Mental Health (U.S.) | 1 | 1997 | 108 | 0.010 |
Why?
|
Plasmids | 3 | 1991 | 2269 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2001 | 13427 | 0.010 |
Why?
|
Hypertension | 1 | 2017 | 8615 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 1246 | 0.010 |
Why?
|
United States | 3 | 2020 | 73180 | 0.010 |
Why?
|
Capsules | 1 | 1997 | 193 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2002 | 19023 | 0.010 |
Why?
|
Models, Animal | 1 | 2002 | 2123 | 0.010 |
Why?
|
Digestive System | 1 | 1997 | 244 | 0.010 |
Why?
|
Gels | 1 | 1997 | 422 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 1998 | 437 | 0.010 |
Why?
|
Emotions | 1 | 2007 | 2768 | 0.010 |
Why?
|
Bacteriuria | 1 | 1995 | 102 | 0.010 |
Why?
|
Astrocytes | 1 | 2002 | 1349 | 0.010 |
Why?
|
Cuba | 1 | 1994 | 48 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11229 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2005 | 8200 | 0.010 |
Why?
|
Enzymes | 1 | 1995 | 254 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2002 | 2252 | 0.010 |
Why?
|
Pilot Projects | 1 | 2007 | 8742 | 0.010 |
Why?
|
Nervous System | 1 | 1997 | 547 | 0.010 |
Why?
|
UTP-Glucose-1-Phosphate Uridylyltransferase | 1 | 1993 | 6 | 0.010 |
Why?
|
Culture Media | 1 | 1995 | 898 | 0.010 |
Why?
|
Carbohydrate Sequence | 1 | 1991 | 411 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2002 | 5505 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1991 | 849 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1995 | 2179 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 1995 | 1149 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1997 | 2359 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2001 | 2682 | 0.010 |
Why?
|
United States Department of Veterans Affairs | 1 | 1995 | 941 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2003 | 9564 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2003 | 4413 | 0.010 |
Why?
|
Age of Onset | 1 | 1997 | 3346 | 0.010 |
Why?
|
Cost Savings | 1 | 1995 | 915 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1993 | 1683 | 0.010 |
Why?
|
Gene Expression | 1 | 2002 | 7602 | 0.010 |
Why?
|
Stem Cells | 1 | 2001 | 3540 | 0.000 |
Why?
|
Nursing Homes | 1 | 1995 | 1084 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1997 | 2059 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1995 | 6242 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2001 | 12809 | 0.000 |
Why?
|
Family | 1 | 1997 | 3208 | 0.000 |
Why?
|
Chromosome Mapping | 1 | 1993 | 4624 | 0.000 |
Why?
|
Disease Outbreaks | 1 | 1994 | 1761 | 0.000 |
Why?
|
Energy Metabolism | 1 | 1995 | 2905 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1982 | 548 | 0.000 |
Why?
|
Genes, Lethal | 1 | 1983 | 224 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 1995 | 5544 | 0.000 |
Why?
|
Nucleic Acid Hybridization | 1 | 1983 | 1305 | 0.000 |
Why?
|
Alzheimer Disease | 1 | 2002 | 8758 | 0.000 |
Why?
|
Molecular Weight | 1 | 1983 | 2173 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 1997 | 15955 | 0.000 |
Why?
|